Plasma protein biosignatures for detection of cardiac allograft vasculopathy

Lin, David; Freue, Gabriela Cohen; Hollander, Zsuzsanna; Mancini, G.B. John; Sasaki, Mayu; Mui, Alice; Wilson-McManus, J.; Ignaszewski, Andrew; Imai, C.; Meredith, Anna; Balshaw, Robert; Ng, Raymond T.; Keown, Paul; McMaster, W. Robert; Carere, Ron; Webb, John G.; McManus, Bruce M.

doi:10.1016/j.healun.2013.04.011

Cited by 29 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, this CE-MS proteomics assay has mainly been studied in chronic kidney disease patients and its value specifically for transplant patients still remains to be evaluated. Other proteomics approaches and signatures in the blood of cardiac 27–29 and kidney transplant patients 30 have been reported. Based on the literature, the proteomics panel in kidney transplant patient to diagnose early acute rejection has been submitted as a Voluntary Exploratory Data Submission to the United States Food and Drug Administration and a regulatory clinical trial is in progress 31 .…”

Section: Predictive Biomarkers In Transplantation Based On Non-targetmentioning

confidence: 99%

Biomarkers in Transplantation—Proteomics and Metabolomics

Christians

Klawitter

2016

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Modern multi-analyte “omics” technologies allow for the identification of molecular signatures that confer significantly more information than measurement of a single parameter as typically used in current medical diagnostics. Proteomics and metabolomics bioanalytical assays capture a large set of proteins and metabolites in body fluids, cells or tissues and, complementing genomics, assess the phenome. Proteomics and metabolomics contribute to the development of novel predictive clinical biomarkers in transplantation in two ways: They can be used to generate a diagnostic fingerprint or they can be used to discover individual proteins and metabolites of diagnostic potential. Much fewer metabolomics than proteomics biomarker studies in transplant patients have been reported and, in contrast to proteomics discovery studies, new lead metabolite markers have yet to emerge. Most clinical proteomics studies have been discovery studies. Several of these studies have assessed diagnostic sensitivity and specificity. Nevertheless, none of these newly discovered protein biomarkers has yet been implemented in clinical decision making in transplantation. The currently most advanced markers discovered in proteomics studies in transplant patients are the chemokines CXCL-9 and CXCL-10, which have successfully been validated in larger multi-center trials in kidney transplant patients. These chemokines can be measured using standard immunoassay platforms, which should facilitate clinical implementation. Based on the published evidence, it is reasonable to expect that these chemokine markers can help guiding and individualizing immunosuppressive regimens, may be able to predict acute and chronic T cell and anti-body mediated rejection and may be useful tools for risk stratification of kidney transplant patients.

show abstract

Section: Predictive Biomarkers In Transplantation Based On Non-targetmentioning

confidence: 99%

Biomarkers in Transplantation—Proteomics and Metabolomics

Christians

Klawitter

2016

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

“…Ensembling was used to combine classifiers by using average or minimum probabilities from the individual classifiers23 to determine whether ensembles improved upon the prognostic performance of the individual classifiers. The performance characteristics of the classifiers were evaluated by leave-one-out cross-validation as described previously24 and included AUC, sensitivity, specificity and net reclassification index (NRI). Biomarker score cut-offs were chosen to maximise sensitivity and Youden's index (sensitivity+specificity – 1) in the discovery cohort.…”

Section: Methodsmentioning

confidence: 99%

Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry

Quon

Dai

Hollander

et al. 2015

Thorax

Self Cite

View full text Add to dashboard Cite

show abstract

“…In relation to treatment and restoring the function of the heart, plasma profiles have been determined to compare different methods in aortic surgery, to find markers of calcific aortic stenosis in patients after aortic valve replacement, and find signatures of both cardiac allograft vasculopathy and recovered heart function . Other investigations of the heart include a study of mitral valve prolapse, where Tan et al evaluated whether plasma biomarkers could be used in the evaluation of mitral regurgitation in patients.…”

Section: Applications Of Isobaric Labeling For Serum and Plasma Protementioning

confidence: 99%

Analysis of the plasma proteome using iTRAQ and TMT‐based Isobaric labeling

Moulder

Bhosale

Goodlett

et al. 2017

Mass Spectrometry Reviews

127

View full text Add to dashboard Cite

Over the past decade, chemical labeling with isobaric tandem mass tags, such as isobaric tags for relative and absolute quantification reagents (iTRAQ) and tandem mass tag (TMT) reagents, has been employed in a wide range of different clinically orientated serum and plasma proteomics studies. In this review the scope of these works is presented with attention to the areas of research, methods employed and performance limitations. These applications have covered a wide range of diseases, disorders and infections, and have implemented a variety of different preparative and mass spectrometric approaches. In contrast to earlier works, which struggled to quantify more than a few hundred proteins, increasingly these studies have provided deeper insight into the plasma proteome extending the numbers of quantified proteins to over a thousand.

show abstract

Plasma protein biosignatures for detection of cardiac allograft vasculopathy

Cited by 29 publications

References 34 publications

Biomarkers in Transplantation—Proteomics and Metabolomics

Biomarkers in Transplantation—Proteomics and Metabolomics

Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry

Analysis of the plasma proteome using iTRAQ and TMT‐based Isobaric labeling

Contact Info

Product

Resources

About